Clinical Trial

CodaMetrix’s AI Platform Now Available in Epic Toolbox to Transform $20B Medical Coding Sector

CodaMetrix’s AI platform, developed with and used by 20 top U.S. health systems, efficiently and accurately transforms patient records into…

1 year ago

Results From European Randomized Controlled Study Using XVIVO’s Heart Technology Published in The Lancet

GOTHENBURG, SWEDEN / ACCESSWIRE / August 16, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, the results of the European randomized…

1 year ago

Genmab Announces Changes to its Executive Committee

Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology OfficerBrad Bailey appointed…

1 year ago

Safety Shot Releases Second Quarter 2024 Results and Corporate Highlights

- Q2 Revenues Increased 40%- Q2 Operating Expenses Decreased 17.7%- Recent Clinical Trial Confirms Dramatic Reduction of Blood Alcohol Content-…

1 year ago

AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company…

1 year ago

Therma Bright’s AI-Powered Digital Cough Technology Being Considered as Partner Technology in New Chronic Cough Drug Clinical Trial

Toronto, Ontario--(Newsfile Corp. - August 16, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a…

1 year ago

4G Clinical Announces Appointment of Life Science Service and Tech Leader Dr. Ronan Brown as New Chief Operating Officer

Brown brings years of industry expertise to oversee and maximize 4G Clinical's operational efficiency and excellence. WELLESLEY, Mass., Aug. 15,…

1 year ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

Potentially pivotal GBM study evaluating lead program, Berubicin, enrollment completed; Topline data expected in the first half of 2025Recent strategic…

1 year ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's…

1 year ago

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBMPart B expected…

1 year ago